Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test Before Immunosuppressive Therapies?
NCT ID: NCT02799316
Last Updated: 2017-06-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2016-06-30
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After acute hepatitis B virus (HBV) infection, the disappearance of hepatitis B surface antigen (HBsAg) had generally been believed to signify viral elimination. However, it now becomes clear that those subjects may have occult HBV infection which is defined as the presence of HBV DNA in the liver in the absence of HBsAg in the serum. Occult HBV infection usually accompanies antibody against hepatitis B core antigen (anti-HBc) and/or antibody against HBsAg (anti-HBs), but some cases might not have these serological markers (seronegative occult HBV infection) .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients
NCT00881036
Impact of Hepatitis B Vaccination on HBs Antigenemia
NCT03193775
Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative
NCT00152880
New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
NCT06906016
HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg
NCT03405597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Considering the lifelong use of multiple antirheumatic drugs, we need more specific guidelines for the management of rheumatic disease patients who are scheduled to receive biological and/or non-biological DMARDs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rheumatic disease with HBs-ag positive
• HBV core antibodies testing. • Real time PCR testing.
HBV core antibodies testing. • Real time PCR testing.
* HBV core antibodies testing in HBV surface antigen negative patients.
* Real time PCR testing for those having positive HBc antibodies.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HBV core antibodies testing. • Real time PCR testing.
* HBV core antibodies testing in HBV surface antigen negative patients.
* Real time PCR testing for those having positive HBc antibodies.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any malignancy e.g. HCC
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Consultant liver and GIT diseases- Tanta university hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rasha A Abdel Noor, Consultant
Role: PRINCIPAL_INVESTIGATOR
Internal medicine department - Tanta university
Sherief Abd-Elsalam, Consultant
Role: STUDY_CHAIR
Division of Gastroenterology and Hepatology- Tanta
Walaa Elkhalawany, Consultant
Role: STUDY_CHAIR
liver diseases dept.-Tanta university hospital
Mona Watani, Consultant
Role: STUDY_CHAIR
liver diseases dept.-Tanta university hospital
Rehab Badawi, Consultant
Role: STUDY_CHAIR
liver diseases dept.-Tanta university hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Rasha Abdelno
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.